HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: An attractive prospect of new targeted agents

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 10, 2012, Pages 1753-1758

  Tavernier, Emmanuelle ^a,b   Flandrin Gresta, Pascale ^b,c   Solly, Françoise ^b,c   Rigollet, Lauren ^c   Cornillon, Jérôme ^a   Augeul Meunier, Karine ^a   Stephan, Jean Louis ^c   Montmartin, Aurélie ^c   Viallet, Annie ^c   Guyotat, Denis ^a,b   Campos, Lydia ^b,c  

^a Cancer Institute Lucien Neuwirth   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Acute lymphoblastic leukaemia; Apoptosis; Bcr Abl; HSP90; New drugs for leukaemia

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; HEAT SHOCK PROTEIN 90; IMATINIB; LIPOCORTIN 5; PROTEIN ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TANESPIMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; POINT MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BENZOQUINONES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFANT; LACTAMS, MACROCYCLIC; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84866743205     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1247-6     Document Type: Article

References (18)

1. Bennet JM, Catovsky D, Daniel MT et al (1976) Proposals for the classification of the acute leukaemias: French-American-British (FAB) cooperative group. Br J Haematol 33:451-458
2. Flandrin P, Guyotat D, Duval A, Cornillon J, Tavernier E, Nadal N, Campos L (2008) Significance of heat-shock protein (HSP90) expression in acute myeloid leukemia cells. Cell Stress Chap-erones 13(3):357-364
3. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, Lorusso PM (2012) A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced unre-sectable breast cancer. Breast Cancer Res Treat 131(3):933-937
4. Goetz MP, Toft DO, Reid JM, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) A phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087
5. Hawkins LM, Jayanthan AA, Narendran A (2005) Effects of 17 AAG on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr Res 57(3):430-437
6. Kaufmann SH, Karp JE, litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Maurer MJ, Smith BD, Peterson KL, Greer J, Chen Y, Reid JM, Ivy Sp, Ames MM, Adjei AA, Erlichman C, Karnitz LM (2011) Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory leukaemia. Haematologica 96(11):1619-1626
7. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR (2010) Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24(4):699-705
8. Lindquist S, Craig EA (1988) The heat shock proteins. Annu Rev Genet 22:631-677
9. Lu Z, Jin Y, Qiu L, Lai Y, Pan J (2010) Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 290(2):182-191
10. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochlo-ride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78(3):626-630
11. Peng C, Brain J, Goodrich A, Kong L, Grayzel D, Pak R, Read M, Li S (2007) Inhibition of heat shock protein 90 prolongs survival of mice with Bcr-Abl-T315I-induced leukaemia and suppresses leukemic stem cells. Blood 110(2):678-685
12. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia 19(7):1198-1206
13. Thomas X, Campos L, Mounier C, Cornillon J, Flandrin P, Le QH, Piselli S, Guyotat D (2005) Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 29(9):1049-1058
14. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A (2010) The synthetic heat shock protein 90 (HSP90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukaemia cells. Invest New Drugs 29(6):1206-1212
15. Tsukahara F, Maru Y (2010) Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood 116(18):3582-3592
16. Wu LX, Xu JH, Zhang KZ, Lin Q, Huang XW, Wen CX, Chen YZ (2008) Disruption of the Bcr-Abl/HSP90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 22(7):1402-1409
17. Young JC, Moarefi I, Hartl UF (2001) HSP 90: a specialized but essential protein-folding tool. J Cell Biol 154(2):267-273
18. Yufu Y, Nishimura J, Nawata H (1992) High constitutive expression of heat shock protein 90 a in human acute leukemia cells. Leuk Res 16(6-7):597-605